Making MDT meetings more effective and safer with Salutare One Referral software

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Multi-Disciplinary Team (MDT) meetings are central to planning complex cancer care but can be slowed by incomplete information, repeated discussions, and administrative burden. This before-and-after study will observe MDT workflow without the software, then with Salutare One Referral in routine meetings, and then again without it to measure changes. MDT members and coordinators will complete questionnaires about feasibility, usability, and safety while the study analyses pseudonymized patient data to identify effects on decision-making and timeliness. The study focuses on implementation effectiveness, safety signals, and practical feasibility in an NHS specialist setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* MDT meeting Panel Members, Coordinators and staff submitting MDT referrals will take part in this study.

Exclusion Criteria:

* MDT meeting Panel Members, Coordinators and staff submitting MDT referrals who are unwilling or unable to take part in the study.

Where it's running

• Royal National Orthopaedic Hospital
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Kevin Moore, MD — Salutare Limited
• Study coordinator: Liba Stones, MA, MBA
• Email: liba@dicro.co.uk
• Phone: +447443940319

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lifileucel (Tumor-infiltrating lymphocytes) for advanced soft tissue sarcoma

  This study tests lifileucel, a cell therapy made from a patient’s own tumor cells, in adults with unresectable or metastatic soft tissue sarcoma who have had prior treatments to see if it helps shrink tumors and improve outcomes.

  Recruiting at 2 sites Phase 2 Iovance Biotherapeutics, Inc. · Tampa, Florida and 1 other locations · NCT07741877

• Domatinostat with Sirolimus for relapsed or refractory sarcoma and osteosarcoma

  This study tests whether the cancer drugs domatinostat and sirolimus together can help adolescents and adults whose sarcoma or osteosarcoma has come back or stopped responding to standard therapy.

  Recruiting at 2 sites Phase 1/2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida and 3 other locations · NCT07725380

• Steroid-Sparing Plan with Olanzapine and Palonosetron to Prevent Nausea in High-Dose Cisplatin

  This phase II trial tests a steroid-sparing regimen using olanzapine and palonosetron to prevent chemotherapy-induced nausea and vomiting in patients getting high-dose cisplatin.

  Recruiting Phase 2 Mahidol University · Bangkok · NCT07699276

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Dietary Supplements and Cancer Patients: Use, Tolerance, and Interactions

  This study looks at how many cancer patients take dietary supplements, how they tolerate them, and whether these supplements interact with cancer treatments.

  Recruiting Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) · Rabat · NCT07670234

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.